Company intelligence / Profile preview

ArrePath

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

ArrePath is advancing novel small molecule antibiotics identified via its AI/ML platform, including AP-001 targeting MDR Enterobacterales for cUTI (funded by CARB-X $3.7M in 2025 for lead optimization); additional programs against common bacterial pathogens and NTM remain pre-clinical.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

CARB-X

Beyond the preview

Go deeper on ArrePath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArrePath.

Explore the full profile